Comparative study of two whole-body imaging techniques in the case of melanoma metastases: Advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT

Laurent, V.; Trausch, Grégory; Bruot, O.; Olivier, Pierre; Felblinger, Jacques; Régent, D

doi:10.1016/j.ejrad.2009.04.059

Cited by 84 publications

(68 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 10% of patients, there was clear improvement in T staging on PET/MR imaging, where T2 HASTE and DWI were most useful and showed the degree of tumor extension into adjacent tissue because of the superior soft-tissue contrast and anatomic detail. It is speculated that any clinical impact will be driven by the MR imaging and CT components of PET/MR imaging and PET/CT and that newer PET radiopharmaceuticals and the addition of dynamic contrast-enhanced MR imaging, DWI, and MR spectroscopy will increase the sensitivity and specificity (23)(24)(25) and may also have a clinical impact. PET/CT is likely to remain the preferred imaging modality for lung and mediastinal nodal disease.…”

Section: Discussionmentioning

confidence: 99%

Qualitative and Quantitative Comparison of PET/CT and PET/MR Imaging in Clinical Practice

et al. 2013

View full text Add to dashboard Cite

The aim of this study was to prospectively compare whole-body PET/MR imaging and PET/CT, qualitatively and quantitatively, in oncologic patients and assess the confidence and degree of inter-and intraobserver agreement in anatomic lesion localization. Methods: Fifty patients referred for staging with known cancers underwent PET/CT with low-dose CT for attenuation correction immediately followed by PET/MR imaging with 2-point Dixon attenuation correction. PET/CT scans were obtained according to standard protocols (56 6 20 min after injection of an average 367 MBq of 18 F-FDG, 150 MBq of 68 Ga-DOTATATE, or 333.8 MBq of 18 F-fluoro-ethyl-choline; 2.5 min/bed position). PET/MR was performed with 5 min/bed position. Three dual-accredited nuclear medicine physicians/radiologists identified the lesions and assigned each to an exact anatomic location. The image quality, alignment, and confidence in anatomic localization of lesions were scored on a scale of 1-3 for PET/CT and PET/MR imaging. Quantitative analysis was performed by comparing the standardized uptake values. Intraclass correlation coefficients and the Wilcoxon signed-rank test were used to assess intra-and interobserver agreement in image quality, alignment, and confidence in lesion localization for the 2 modalities. Results: Two hundred twenty-seven tracer-avid lesions were identified in 50 patients. Of these, 225 were correctly identified on PET/CT and 227 on PET/MR imaging by all 3 observers. The confidence in anatomic localization improved by 5.1% when using PET/MR imaging, compared with PET/CT. The mean percentage interobserver agreement was 96% for PET/CT and 99% for PET/MR imaging, and intraobserver agreement in lesion localization across the 2 modalities was 93%. There was 10% (5/50 patients) improvement in local staging with PET/MR imaging, compared with PET/CT. Conclusion: In this first study, we show the effectiveness of whole-body PET/MR imaging in oncology. There is no statistically significant difference between PET/MR imaging and PET/CT in respect of confidence and degree of inter-and intraobserver agreement in anatomic lesion localization. The PET data on both modalities were similar; however, the observed superior soft-tissue resolution of MR imaging in head and neck, pelvis, and colorectal cancers and of CT in lung and mediastinal nodal disease points to future tailored use in these locations.

show abstract

Section: Discussionmentioning

confidence: 99%

Qualitative and Quantitative Comparison of PET/CT and PET/MR Imaging in Clinical Practice

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Furthermore, benign lesions can have the appearance of hyperintensity on DW MRI because they can contain fat cells, pus, edema, cyst, scar tissue, fibrous tissue and necrotic tissue and this can hinder the movement of water molecules. On MRI, age related f Biomedical Gr kull [10] . Our pat n and bone thi MRI appearanc RI [11] .…”

Section: Discussionmentioning

confidence: 99%

Characterization of a parietal lesion detected by diffusion weighted MRI, NaF18-PET/CT and CT

Win

Aparici

2013

JBGC

View full text Add to dashboard Cite

It is very important to accurately characterize skull lesions so that appropriate treatment decisions can be made. False positive readings may lead to unnecessary surgical intervention or radiation. We present a case of a parietal lesion seen on Diffusion weighted (DW) MRI, and further characterized with NaF18-PET/CT and CT in a 69 year old male. This is the first case to report the use of DW MRI, NaF18-PET/CT bone scan and CT in the diagnosis of a skull lesion. DW MRI is known to have high specificity to detect malignant lesions in the skull. If a similar case such as ours in encountered in everyday clinical practice, a differential diagnosis of a benign etiology should be considered.

show abstract

“…Although FDG-PET/CT is reported to be superior than CT in the evaluation of lymph node metastases of lung cancer, it is Diagnosis of staging for lung cancer by whole-body DWI Some reported that the diagnostic ability of wholebody DWI (WB-DWI) was equivalent to that of FDG-PET/CT, 34,35) others reported that the diagnostic ability of WB-DWI was superior to that of FDG-PET/CT. 36) In this decade, clinical staging of lung cancer is usually performed by FDG-PET/CT and brain MRI. FDG-PET/ CT cannot assess brain metastasis because of metabolism of glucose in the brain, and brain MRIs make up for the disadvantage of FDG-PET/CT.…”

Section: Diagnosis Of Lung Cancer and The Pulmonary Nodule And Massmentioning

confidence: 99%

Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer

Usuda

Funazaki

Maeda

et al. 2017

ATCS

View full text Add to dashboard Cite

IntroductionThis paper focuses on the latest research of diffusion-weighted magnetic resonance imaging (DWI), and deals with economic benefits, diagnostic benefits, and prospects of DWI for lung cancer. The medical cost of a magnetic resonance imaging (MRI) is 81%-84% cheaper than that of 18-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT). DWI is reported to be useful for differential diagnosis of malignancy or benignity for neoplasm in various organs. Diagnostic efficacy by DWI for pulmonary nodules and masses and the evaluation of N factor and M factor in lung cancer are equivalent to or more than that of FDG-PET/CT. The diagnostic capability of wholebody DWI (WB-DWI) for the staging of clinically operable lung cancers is equivalent to that of FDG-PET/CT and brain MRI, and WB-DWI is now becoming a more main stream procedure. Although the diagnostic performance of DWI for lung cancer may be equivalent to that of FDG-PET/CT, prospective randomized controlled trial for comparison of diagnostic efficacy between FDG-PET/CT and DWI for lung cancer is necessary for an accurate comparison. DWI may have an advantage in the aspect of the cost and diagnostic efficacy in lung cancer management.

show abstract

Comparative study of two whole-body imaging techniques in the case of melanoma metastases: Advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT

Cited by 84 publications

References 20 publications

Qualitative and Quantitative Comparison of PET/CT and PET/MR Imaging in Clinical Practice

Qualitative and Quantitative Comparison of PET/CT and PET/MR Imaging in Clinical Practice

Characterization of a parietal lesion detected by diffusion weighted MRI, NaF18-PET/CT and CT

Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer

Contact Info

Product

Resources

About